Author

John Jr. Hynes

Observed names: J. JUN. HYNES, John Hynes, John Hynes Jr., John Hynes,, John Hynes, Jr., John Hynes, Jr.,

Institution: Bristol-Myers Squibb (United States)

Observed institutions: Merck & Co., Inc., Rahway, NJ, USA (United States), University of California, Irvine, Bristol-Myers Squibb (United States), University of Pennsylvania

ORCID: 0000-0002-0490-5179

Observed ORCID: 0000-0002-0490-5179

OpenAlex ID: A5056190867

Modulation of Receptor and Receptor Subtype Affinities Using Diastereomeric and Enantiomeric Monosaccharide Scaffolds as a Means to Structural and Biological Diversity. A New Route to Ether Synthesis

1998 · Ralph Hirschmann, John Hynes,, et al. · Journal of Medicinal Chemistry · 107

Copper-Catalyzed Chlorination of Functionalized Arylboronic Acids

2010 · Hong Wu, John Hynes · Organic Letters · 92

Design, Synthesis, and Anti-inflammatory Properties of Orally Active 4-(Phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38α Mitogen-Activated Protein Kinase Inhibitors

2007 · John Hynes, Alaric J. Dyckman, et al. · Journal of Medicinal Chemistry · 85

N-Amination of Pyrrole and Indole Heterocycles with Monochloramine (NH2Cl)

2004 · John Hynes,, Wendel W. Doubleday, et al. · The Journal of Organic Chemistry · 82

DBS Sampling Can be Used to Stabilize Prodrugs in Drug Discovery Rodent Studies without the Addition of Esterase Inhibitors

2010 · Celia J D’Arienzo, Qin C Ji, et al. · Bioanalysis · 77

Selective IRAK4 Inhibition Attenuates Disease in Murine Lupus Models and Demonstrates Steroid Sparing Activity

2016 · Shailesh Dudhgaonkar, Sourabh Ranade, et al. · The Journal of Immunology · 74

Small Molecule p38 Inhibitors: Novel Structural Features and Advances from 2002-2005

2005 · John Hynes, Jr., Katerina Leftheris · Current Topics in Medicinal Chemistry · 70

Synthesis of Potent Cyclic Hexapeptide NK-1 Antagonists. Use of a Minilibrary in Transforming a Peptidal Somatostatin Receptor Ligand into an NK-1 Receptor Ligand via a Polyvalent Peptidomimetic

1996 · Ralph Hirschmann, Wenqing Yao, et al. · Journal of Medicinal Chemistry · 59

Discovery of 4-(5-(Cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a Clinical p38α MAP Kinase Inhibitor for the Treatment of Inflammatory Diseases

2010 · Chunjian Liu, James Lin, et al. · Journal of Medicinal Chemistry · 57

Rational Design and Synthesis of an Orally Active Indolopyridone as a Novel Conformationally Constrained Cannabinoid Ligand Possessing Antiinflammatory Properties

2003 · Stephen T. Wrobleski, Ping Chen, et al. · Journal of Medicinal Chemistry · 57

Design and Synthesis of Novel Scaffolds for Drug Discovery: Hybrids of β- d -Glucose with 1,2,3,4-Tetrahydrobenzo[e][1,4]diazepin-5-one, the Corresponding 1-Oxazepine, and 2- and 4-Pyridyldiazepines

2001 · Leïla Abrous, John Hynes, et al. · Organic Letters · 54

Discovery of the CCR1 Antagonist, BMS-817399, for the Treatment of Rheumatoid Arthritis

2014 · Joseph B. Santella, Daniel S. Gardner, et al. · Journal of Medicinal Chemistry · 53

Biologic-like In Vivo Efficacy with Small Molecule Inhibitors of TNFα Identified Using Scaffold Hopping and Structure-Based Drug Design Approaches

2020 · Hai-Yun Xiao, Ning Li, et al. · Journal of Medicinal Chemistry · 52

The Discovery of Orally Active Triaminotriazine Aniline Amides as Inhibitors of p38 MAP Kinase

2004 · Katerina Leftheris, Gulzar Ahmed, et al. · Journal of Medicinal Chemistry · 50

Rationally Designed, Conformationally Constrained Inverse Agonists of RORγt—Identification of a Potent, Selective Series with Biologic-Like in Vivo Efficacy

2019 · David Marcoux, James J.-W. Duan, et al. · Journal of Medicinal Chemistry · 41

Utilization of a nitrogen–sulfur nonbonding interaction in the design of new 2-aminothiazol-5-yl-pyrimidines as p38α MAP kinase inhibitors

2010 · Shuqun Lin, Stephen T. Wrobleski, et al. · Bioorganic & Medicinal Chemistry Letters · 35

C-3 Amido-Indole cannabinoid receptor modulators

2002 · John Hynes, Katerina Leftheris, et al. · Bioorganic & Medicinal Chemistry Letters · 33

Discovery of highly potent, selective, covalent inhibitors of JAK3

2017 · James Kempson, Damaso Ovalle, et al. · Bioorganic & Medicinal Chemistry Letters · 32

Synthesis and SAR of new pyrrolo[2,1-f][1,2,4]triazines as potent p38α MAP kinase inhibitors

2008 · Stephen T. Wrobleski, Shuqun Lin, et al. · Bioorganic & Medicinal Chemistry Letters · 32

Novel Chimeric Scaffolds to Extend the Exploration of Receptor Space: Hybrid β- d -Glucose−Benzoheterodiazepine Structures for Broad Screening. Effect of Amide Alkylation on the Course of Cyclization Reactions

2003 · Leïla Abrous, Patrick A. Jokiel, et al. · The Journal of Organic Chemistry · 31

Discovery of pyrrolo[1,2-b]pyridazine-3-carboxamides as Janus kinase (JAK) inhibitors

2014 · James J.-W. Duan, Zhonghui Lu, et al. · Bioorganic & Medicinal Chemistry Letters · 30

Intramolecular Heck cyclization of α-sulfenyl enol triflates. Asymmetric synthesis of a pentacyclic cardenolide precursor having functionality at C-11

1998 · John Hynes, Larry E Overman, et al. · Tetrahedron Letters · 30

Developing Adnectins That Target SRC Co-Activator Binding to PXR: A Structural Approach toward Understanding Promiscuity of PXR

2015 · Javed A. Khan, Daniel M. Camac, et al. · Journal of Molecular Biology · 27

PDF

The discovery of (R)-2-(sec-butylamino)-N-(2-methyl-5-(methylcarbamoyl)phenyl) thiazole-5-carboxamide (BMS-640994)—A potent and efficacious p38α MAP kinase inhibitor

2008 · John Hynes, Hong Wu, et al. · Bioorganic & Medicinal Chemistry Letters · 27

Identification of a Potent, Selective, and Efficacious Phosphatidylinositol 3-Kinase δ (PI3Kδ) Inhibitor for the Treatment of Immunological Disorders

2017 · Qingjie Liu, Qing Shi, et al. · Journal of Medicinal Chemistry · 25

Works count: 55

Citation count: 1,574

H-index: 25

I10-index: 40